FDA preemption arises where federal requirements make compliance with a state law duty impossible or where federal law occupies the field. The doctrine differs by product category and approval route.
Generic drug manufacturers cannot unilaterally change labeling, which supports impossibility preemption of failure to warn claims, while brand manufacturers have more latitude and correspondingly less protection.
Alternative Names:
Drug and Device Preemption, Pharmaceutical Preemption
Why it Matters?
This defense determines whether entire categories of pharmaceutical and device litigation are viable. The brand and generic distinction has been outcome-determinative for large numbers of claimants, and for brand drugs the analysis turns on whether newly acquired information would have permitted a labeling change, which is a fact-intensive inquiry rather than a clean legal bar.
Frequently Confused with
Related terms
Frequently asked questions
Why are generic drug claims often preempted?
Are brand manufacturers protected?
